Literature DB >> 1719464

Effect of herbimycin A on growth and pp60c-src activity in human colon tumor cell lines.

R Garcia1, N U Parikh, H Saya, G E Gallick.   

Abstract

The effect of herbimycin A, an ansamycin antibiotic which inhibits cellular transformation by retroviral tyrosine kinases, on the monolayer growth of seven colon tumor cell lines and one cell line established from normal colonic mucosa, CCL239, was examined. Each colon tumor cell line tested showed dose-dependent growth inhibition in response to herbimycin A. A 125ng ml-1 dose of the antibiotic caused greater than 40% growth inhibition in all colon tumor cell lines after two cell doublings. In contrast, at similar herbimycin A concentrations only 12% inhibition was observed in 'normal' CCL239 cells. No major morphologic changes were observed at the light microscopic level in any of the tumor cell lines or CCL239 cells in response to treatment with herbimycin A. Studies using the HT29 colon adenocarcinoma cell line showed dose-dependent inactivation of pp60c-src by herbimycin A, resulting in decreased autophosphorylation, enolase phosphorylation and steady-state levels, which correlated with cellular growth inhibition. Herbimycin A-induced reductions in pp60c-src kinase activity preceded changes in pp60c-src steady-state levels. Growth and pp60c-src inhibition were reversible following removal of herbimycin A from cell culture media. Our results suggest that regulation of pp60c-src tyrosine kinase activity may be important in growth control of colon tumor cells.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1719464

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  10 in total

Review 1.  Demystified ... oncogenes.

Authors:  Y L Wallis; F Macdonald
Journal:  Mol Pathol       Date:  1999-04

2.  Intestinal HT-29 cells with dysfunction of E-cadherin show increased pp60src activity and tyrosine phosphorylation of p120-catenin.

Authors:  A Skoudy; M D Llosas; A García de Herreros
Journal:  Biochem J       Date:  1996-07-01       Impact factor: 3.857

3.  pp60v-src transformation of rat cells but not chicken cells strongly correlates with low-affinity phosphopeptide binding by the SH2 domain.

Authors:  M F Verderame
Journal:  Mol Biol Cell       Date:  1997-05       Impact factor: 4.138

4.  Geldanamycin disrupts platelet-membrane structure, leading to membrane permeabilization and inhibition of platelet aggregation.

Authors:  S Suttitanamongkol; A R Gear; R Polanowska-Grabowska
Journal:  Biochem J       Date:  2000-01-15       Impact factor: 3.857

5.  Transcriptional suppression of the human T-cell leukemia virus type I long terminal repeat occurs by an unconventional interaction of a CREB factor with the R region.

Authors:  X Xu; D A Brown; I Kitajima; J Bilakovics; L W Fey; M I Nerenberg
Journal:  Mol Cell Biol       Date:  1994-08       Impact factor: 4.272

6.  Elevated c-Src tyrosine kinase activity in premalignant epithelia of ulcerative colitis.

Authors:  C A Cartwright; C A Coad; B M Egbert
Journal:  J Clin Invest       Date:  1994-02       Impact factor: 14.808

7.  Intercellular signalling within vascular cells under high D-glucose involves free radical-triggered tyrosine kinase activation.

Authors:  G Schaeffer; S Levak-Frank; M M Spitaler; E Fleischhacker; V E Esenabhalu; A H Wagner; M Hecker; W F Graier
Journal:  Diabetologia       Date:  2003-06-13       Impact factor: 10.122

8.  Cell-cycle arrest and p53 accumulation induced by geldanamycin in human ovarian tumour cells.

Authors:  A J McIlwrath; V G Brunton; R Brown
Journal:  Cancer Chemother Pharmacol       Date:  1996       Impact factor: 3.333

9.  Increase in activity and level of pp60c-src in progressive stages of human colorectal cancer.

Authors:  M S Talamonti; M S Roh; S A Curley; G E Gallick
Journal:  J Clin Invest       Date:  1993-01       Impact factor: 14.808

10.  Preclinical pharmacologic evaluation of geldanamycin as an antitumor agent.

Authors:  J G Supko; R L Hickman; M R Grever; L Malspeis
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.